Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers

CITIUS ONCOLOGY, INC.

24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.
No unexpected safety signals or serious immune-related adverse events observed in 25 evaluable patients.
Investigator-initiated trial by University of Pittsburgh; full results expected at upcoming international cancer conference.
Study evaluated LYMPHIR (denileukin diftitox-cxdl) + pembrolizumab in relapsed/refractory ovarian and endometrial cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.